{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-008273","form_type":"8-K","ticker":"ERNA","cik":"0000748592","company_name":"Ernexa Therapeutics Inc.","filed_at":"2024-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.858441+00:00","generated_at":"2026-06-06T00:31:09.326092+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Eterna Therapeutics appoints Peter Cicala to Board of Directors","bullets":["Appointed Feb 12, 2024, effective immediately; independent director under Nasdaq rules.","Serves on Audit, Compensation, and Nominating & Corporate Governance Committees.","Receives standard non-employee director compensation per 2023 proxy statement.","No material interest transactions or arrangements with other persons."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-008273","json":"https://secwatch.observer/filing/0001140361-24-008273.json","markdown":"https://secwatch.observer/filing/0001140361-24-008273.md","text":"https://secwatch.observer/filing/0001140361-24-008273.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/748592/000114036124008273/0001140361-24-008273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/748592/000114036124008273/ef20021627_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T00:31:09.326092+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c66e3c3a12","claim":"Peter Cicala was appointed as Director at Ernexa Therapeutics Inc..","evidence_excerpt":"On February 12, 2024, and effective as of that date, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors (the “Board”) of Eterna Therapeutics Inc. (the “Company”) appointed Mr. Peter Cicala to the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000114036124008273/0001140361-24-008273-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}